Skip to main content

Table 1 Summary of FDA-approved anti-angiogenic agents

From: The role of microenvironment in tumor angiogenesis

Anti-angiogenic agents Manufacturer Target Date of first FDA approval Condition
Bevacizumab
(Avastin)
Genentech VEGF 2004. 02 Metastatic colorectal cancer, non-squamous small cell lung cancer,
cervical cancer, ovarian cancer,
metastatic breast cancer,
malignant glioma
Ramucirumab
(Cyramza)
ImClone VEGFR2 2014. 04 Advanced gastric or gastroesophageal adenocarcinoma, non-small-cell lung cancer, and metastatic urinary tract epithelial cancer
Ziv-aflibercept
(Zaltrap)
Sanofi VEGFA/VEGFB /PIGF 2012. 08 Metastatic colorectal cancer
Axitinib
(Inlyta)
Pfizer VEGFR/KIT/PDGFR/RET/ CSF1R/FLT3 2012. 01 Advanced renal cell carcinoma
Sorafenib (Nexavar) Bayer VEGFR2/PDGFR /KIT/FLT3/BRAF 2005. 12 Renal cell and hepatocellular carcinoma and thyroid cancer
Sunitinib
(Sutent)
Pfizer VEGFR/KIT /PDGFR 2006. 01 Gastrointestinal stromal tumors, advanced renal cancer, and metastatic well-differentiated advanced pancreatic neuroendocrine tumors
Regorafenib
(Stivqrga)
Bayer VEGFR/PDGFR /KIT/FGFR 2012. 09 Metastatic colorectal cancer, gastrointestinal mesenchymal
liver cancer
Nintedanib
(OFEV)
Boehringer
lngelheim
VEGFR/PDGFR /FGFR 2014. 10 Idiopathic pulmonary fibrosis, non-small cell lung cancer
Cabozantinib
(Cabometyx)
Exelixis RET/VEGFR2 /PDGFR/KIT/FLT3/ MET/AXL 2012. 11 Metastatic thyroid cancer, non-small cell lung cancer with c-Met amplification
Pazopanib
(Votrient)
GlaxoSmithKline VEGFR/PDGFR
/KIT
2009. 10 Advanced renal cancer, advanced soft tissue sarcoma, epithelial ovarian cancer, non-small cell lung cancer
\